Karolinska Development: Our view to clinical advancement of Forendo project

Research Note

2019-03-07

15:15

Earlier today, Karolinska Development (KD) announced that their portfolio company, Forendo Pharma, has advanced in the clinic with their lead candidate, FOR-6219. It is positive news per se and represents an upside opportunity as this project is currently not included in our valuation.

AH

Anders Hedlund

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.